EP0708658A4 - Recombinant cytomegalovirus vaccine - Google Patents

Recombinant cytomegalovirus vaccine

Info

Publication number
EP0708658A4
EP0708658A4 EP94915386A EP94915386A EP0708658A4 EP 0708658 A4 EP0708658 A4 EP 0708658A4 EP 94915386 A EP94915386 A EP 94915386A EP 94915386 A EP94915386 A EP 94915386A EP 0708658 A4 EP0708658 A4 EP 0708658A4
Authority
EP
European Patent Office
Prior art keywords
cytomegalovirus vaccine
recombinant cytomegalovirus
recombinant
vaccine
cytomegalovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94915386A
Other languages
German (de)
French (fr)
Other versions
EP0708658A1 (en
Inventor
Stanley A Plotkin
Robert P Ricciardi
Eva Gonczol
Klara Berencsi
Robert F Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Wistar Institute of Anatomy and Biology
Original Assignee
US Department of Health and Human Services
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Wistar Institute of Anatomy and Biology filed Critical US Department of Health and Human Services
Publication of EP0708658A1 publication Critical patent/EP0708658A1/en
Publication of EP0708658A4 publication Critical patent/EP0708658A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP94915386A 1993-04-16 1994-04-15 Recombinant cytomegalovirus vaccine Withdrawn EP0708658A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4897893A 1993-04-16 1993-04-16
US48978 1993-04-16
PCT/US1994/004180 WO1994023744A1 (en) 1993-04-16 1994-04-15 Recombinant cytomegalovirus vaccine

Publications (2)

Publication Number Publication Date
EP0708658A1 EP0708658A1 (en) 1996-05-01
EP0708658A4 true EP0708658A4 (en) 1997-05-21

Family

ID=21957451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94915386A Withdrawn EP0708658A4 (en) 1993-04-16 1994-04-15 Recombinant cytomegalovirus vaccine

Country Status (3)

Country Link
EP (1) EP0708658A4 (en)
CA (1) CA2160583A1 (en)
WO (1) WO1994023744A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
EP0914441A2 (en) 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
WO1998034635A1 (en) * 1997-02-07 1998-08-13 The Wistar Institute Methods and compositions for the inhibition of interleukin-12 production
US6586192B1 (en) 1998-05-29 2003-07-01 Thomas Jefferson University Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP2184296A1 (en) 2000-07-19 2010-05-12 Advanced Research And Technology Institute, Inc. Fibroblast growth factor (fgf23) and methods for use
JP3966819B2 (en) 2001-05-24 2007-08-29 キム，スーギョン Novel second keratinocyte growth factor analogue present in the hair follicle
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
CA2568344C (en) 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7608433B2 (en) 2005-02-09 2009-10-27 Idexx Laboratories Method of detection of classical swine fever
MX2008006313A (en) 2005-11-15 2008-11-06 Philadelphia Children Hospital Reactive dyestuffs, method for the production thereof, and use of the same.
DE602005023550D1 (en) 2005-12-14 2010-10-21 Licentia Ltd Uses of a neurotrophic factor
JP2009528293A (en) 2006-02-23 2009-08-06 ザ チルドレンズ ホスピタル オブ フィラデルフィア Compositions and methods for regulating hemostasis using various forms of activated factor V
CA2673085C (en) 2006-12-12 2013-10-15 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
FI20070808A0 (en) 2007-10-25 2007-10-25 Mart Saarma Split variants of GDNF and uses thereof
FI20080326A0 (en) 2008-04-30 2008-04-30 Licentia Oy Neurotrophic factor MANF and its uses
JP2012509670A (en) 2008-11-21 2012-04-26 ザ チルドレンズ ホスピタル オブ フィラデルフィア Snake fifth factor as a blood coagulation promoter and method of use
WO2012074868A2 (en) 2010-12-03 2012-06-07 Ms Technologies, Llc Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
CA2850603C (en) 2011-09-30 2021-11-16 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
US9783817B2 (en) 2013-03-04 2017-10-10 Arkansas State University Methods of expressing and detecting activity of expansin in plant cells
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
WO2018226887A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
US20200390814A1 (en) 2018-02-02 2020-12-17 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
JP2023546113A (en) 2020-10-15 2023-11-01 エフ． ホフマン－ラ ロシュ アーゲー Nucleic acid constructs for simultaneous gene activation
KR20230085929A (en) 2020-10-15 2023-06-14 에프. 호프만-라 로슈 아게 Nucleic acid constructs for VA RNA transcription
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
AR129500A1 (en) 2022-06-03 2024-09-04 Hoffmann La Roche METHOD FOR PRODUCING RECOMBINANT AAV PARTICLES
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles
WO2024165456A1 (en) 2023-02-07 2024-08-15 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies
WO2024194280A1 (en) 2023-03-21 2024-09-26 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000062A1 (en) * 1988-07-01 1990-01-11 The Children's Hospital, Incorporated Antibody recognition of fragments from cytomegalovirus
WO1990006771A1 (en) * 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
EP0389286A2 (en) * 1989-03-24 1990-09-26 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1990011302A1 (en) * 1989-03-24 1990-10-04 University Of Iowa Research Foundation Antibody and t cell recognition sites on glycoproteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000062A1 (en) * 1988-07-01 1990-01-11 The Children's Hospital, Incorporated Antibody recognition of fragments from cytomegalovirus
WO1990006771A1 (en) * 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
EP0389286A2 (en) * 1989-03-24 1990-09-26 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1990011302A1 (en) * 1989-03-24 1990-10-04 University Of Iowa Research Foundation Antibody and t cell recognition sites on glycoproteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERENCSI ET AL: "HUMAN CYTOMEGALOVIRUS (HCMV) GLYCOPROTEIN-B (GB)-SPECIFIC CELL-MEDIATED IMMUNITY IN EXPERIMENTAL ANIMALS", ACTA MICROBIOLOGICA HUNGARICA, vol. 38, 1991, pages 170 - 171, XP000645013 *
BERENCSI ET AL: "MURINE CYTOTOXIC T CELL RESPONSE SPECIFIC FOR HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B (GB) INDUCED BY ADENOVIRUS AND VACCINIA VIRUS RECOMBINANTS EXPRESSING GB", JOURNAL OF GENERAL VIROLOGY, vol. 74, November 1993 (1993-11-01), pages 2507 - 2512, XP002026070 *
LIU ET AL: "THE N-TERIMINAL 513 AMINO ACIDS OF THE ENVELOPE GLYCOPROTEIN GB OF HUMAN CYTOMEGALOVIRUS STIMLATES BOTH B- AND T-CELL IMMUNE RESPONSES IN HUMANS", JOURNAL OF VIROLOGY, vol. 65, no. 3, March 1991 (1991-03-01), pages 1644 - 1648, XP000645036 *
See also references of WO9423744A1 *

Also Published As

Publication number Publication date
EP0708658A1 (en) 1996-05-01
CA2160583A1 (en) 1994-10-27
WO1994023744A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
EP0708658A4 (en) Recombinant cytomegalovirus vaccine
GB9115909D0 (en) Recombinant dna
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
CZ197595A3 (en) Vaccine preparations
ZA947828B (en) Vaccines
GB9325496D0 (en) Vaccines
IL101639A0 (en) Recombinant influenza vaccines
AU6715094A (en) Recombinant vaccine
EP0710120A4 (en) Recombinant swinepox virus
GB9215233D0 (en) Vaccines
AU2347692A (en) Recombinant viral vaccine
GB9322702D0 (en) Vaccines
GB9214871D0 (en) Vaccines
GB9202933D0 (en) Vaccines
GB9213559D0 (en) Vaccines
GB9201023D0 (en) Vaccines
GB9322808D0 (en) Vaccines
GB9226768D0 (en) Vaccines
GB9304962D0 (en) Recombinant virus
ZA945843B (en) Recombinant adenovirus vaccines
GB9220010D0 (en) Recombinant virus
ZA933541B (en) Vaccines
GB9106568D0 (en) Recombinant antigen
GB9324964D0 (en) Viral vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/00

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990316

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030730